BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Digklia A, Voutsadakis IA. Eribulin for heavily pre-treated metastatic breast cancer patients. World J Exp Med 2015; 5(3): 194-199 [PMID: 26309821 DOI: 10.5493/wjem.v5.i3.194]
URL: https://www.wjgnet.com/2220-315x/full/v5/i3/194.htm
Number Citing Articles
1
Yasuko Kikuchi, Yoshihiro Uchida, Kazuo Shirakawa, Hajime Kanauchi, Takayoshi Niwa, Kotoe Nishioka, Keiichirou Tada, Masanori Hashimoto, Hidemitsu Yasuda, Ryoko Sugiura, Hidetaka Kawabata, Yasuyuki Seto, Toshihisa Ogawa. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimensAsia-Pacific Journal of Clinical Oncology 2018; 14(5): e231 doi: 10.1111/ajco.12863
2
Erica Quaquarini, Federico Sottotetti, Daniela D’Ambrosio, Alberto Malovini, Stefania Morganti, Arianna Marinello, Lorenzo Pavesi, Mara Frascaroli. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patientsFuture Oncology 2017; 13(11s): 11 doi: 10.2217/fon-2016-0517
3
Ioannis A. Voutsadakis. A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancerAnti-Cancer Drugs 2017; 28(5): 557 doi: 10.1097/CAD.0000000000000493
4
Murat Sari, Pınar Saip. Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real lifeIndian Journal of Cancer 2020; 57(1): 55 doi: 10.4103/ijc.IJC_458_18